SciELO - Scientific Electronic Library Online

 
vol.65 número3Should male children be vaccinated against human papillomavirus?Implications of technical-instrumental rationality in health education: pending challenges índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de la Facultad de Medicina

versão impressa ISSN 0120-0011

rev.fac.med. vol.65 no.3 Bogotá jul./set. 2017

https://doi.org/10.15446/revfacmed.v65n3.63104 

Letters to the editor

Vaccination against HPV in Brazil: What is New in the Year 2017?

Vacinação contra o Papilomavírus Humano no Brasil: o que há de novo em 2017?

Marcos Roberto Tovani-Palone1 

Taís Tovani-Sanches2  * 

1 University of São Paulo - Faculty of Medicine of Ribeirão Preto - Ribeirão Preto - São Paulo - Brazil.

2 Cesumar University Center - Course of Medicine of the Cesumar University Center - Maringá - Paraná - Brazil.


Dear editor,

We would like to discuss briefly new information regarding the article "Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes" 1.

In 2017, the Ministry of Health of Brazil started to implement the quadrivalent vaccination against human papillomavirus (HPV) for boys aged 12 to 13 years, thus making Brazil the first South American country that offers this vaccine for boys in the National Immunization Calendar through mass vaccination 2,3. In addition, the age group for vaccination of children and adolescent girls against HPV was extended from 9 to 14 years 2.

It is worth mentioning that in 2020, the vaccination of boys will be done beginning at age 9 2,3. Today, vaccination against HPV is still provided to girls aged 9 to 26 years infected with human immunodeficiency virus (HIV), and vaccination to boys with the same condition was initiated in 2017 2.

All these changes intend to decrease the number of HPV infection cases, as well as related deaths 3. However, according to Sanches et al. (2017), several barriers have been found that hinder the effective implementation of the vaccination against HPV in children and adolescents 1.

In consequence, we believe that improvements are necessary, especially regarding health education in schools and specific professional training to attend to the needs of this age group. Only when these requirements are met, it can be possible to provide adequate assistance to these individuals, with a significant increase in vaccination rates.

Acknowledgements

None declared by the authors.

References

1. Sanches TT, Siqueira-Oliveira T, Papp-Moretti C, Tovani-Palone MR, Hishinuma G. Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes. Rev. Fac. Med. 2017;65(1):115-20. http://doi.org/cd86. [ Links ]

2. Brasil. Ministério da Saúde. Nota Informativa No. 311, de 2016/CGPNI/ DEVIT/SVS/MS. Mudanças no Calendário Nacional de Vacinação para o ano de 2017. Brasília: Secretaria de Vigilância em Saúde; 2016 [cited 2017 Mar 04]. Available from: Available from: https://goo.gl/mEHNyv . [ Links ]

3. Portal Brasil. Tire dúvidas sobre a vacinação contra o HPV para meninos. Governo do Brasil; 2017 [cited 2017 Mar 04]. Available from: Available from: https://goo.gl/WbRnWg . [ Links ]

1Tovani-Palone MR, Tovani-Sanches T. Vaccination against HPV in Brazil: What is New in the Year 2017? Rev. Fac. Med. 2017;65(3):539. English. doi: http://dx.doi.org/10.15446/revfacmed.v65n3.63104.

2Tovani-Palone MR, Tovani-Sanches T. [Vacinação contra o Papilomavírus Humano no Brasil: o que há de novo em 2017?]. Rev. Fac. Med. 2017;65(3):539. English. doi: http://dx.doi.org/10.15446/revfacmed.v65n3.63104.

Funding None declared by the authors.

Received: March 05, 2017; Accepted: March 22, 2017

*Corresponding author: Taís Tovani-Sanches. Cesumar University Center. Av. Guedner, 1610, Zona 8, CEP 87050-900. Phone number: +55 44 30276360. Maringá. Brazil. Email: tais.sanches1@gmail.com.

Conflicts of interest

None declared by the authors.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License